Tahseen Mozaffar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11424236/publications.pdf

Version: 2024-02-01

62 papers	4,380 citations	147801 31 h-index	118850 62 g-index
65 all docs	65 docs citations	65 times ranked	4675 citing authors

#	Article	IF	Citations
1	Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 2016, 375, 511-522.	27.0	695
2	Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurology, The, 2007, 6, 1045-1053.	10.2	610
3	Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurology, The, 2021, 20, 526-536.	10.2	194
4	A randomized, doubleâ€blind, placeboâ€controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle and Nerve, 2013, 48, 76-84.	2.2	187
5	An overview of polymyositis and dermatomyositis. Muscle and Nerve, 2015, 51, 638-656.	2.2	176
6	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology, 2019, 92, e2661-e2673.	1.1	169
7	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
8	Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis. JAMA Neurology, 2020, 77, 582.	9.0	126
9	Chronic nerve compression induces local demyelination and remyelination in a rat model of carpal tunnel syndrome. Experimental Neurology, 2004, 187, 500-508.	4.1	110
10	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64.	1.1	106
11	Compressive Neuropathies of the Upper Extremity: Update on Pathophysiology, Classification, and Electrodiagnostic Findings. Journal of Hand Surgery, 2010, 35, 668-677.	1.6	76
12	Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology, 2016, 86, 813-820.	1.1	70
13	A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 212-222.	2.1	67
14	Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurology, The, 2021, 20, 1012-1026.	10.2	59
15	A progressive translational mouse model of human valosinâ€containing protein disease: The VCP^{R155H/+} mouse. Muscle and Nerve, 2013, 47, 260-270.	2.2	58
16	Clinical correlates of granulomas in muscle. Journal of Neurology, 1998, 245, 519-524.	3.6	56
17	The Homozygote VCPR155H/R155H Mouse Model Exhibits Accelerated Human VCP-Associated Disease Pathology. PLoS ONE, 2012, 7, e46308.	2.5	56
18	Local down-regulation of myelin-associated glycoprotein permits axonal sprouting with chronic nerve compression injury. Experimental Neurology, 2006, 200, 418-429.	4.1	54

#	Article	IF	Citations
19	Valosin-containing protein mutation and Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2012, 18, 107-109.	2.2	53
20	Schwann cells upregulate vascular endothelial growth factor secondary to chronic nerve compression injury. Muscle and Nerve, 2005, 31, 452-460.	2.2	52
21	Chronic nerve compression alters schwann cell myelin architecture in a murine model. Muscle and Nerve, 2012, 45, 231-241.	2.2	50
22	Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Molecular Genetics and Metabolism, 2016, 119, 115-123.	1.1	49
23	Matrix metalloproteinase 3 deletion preserves denervated motor endplates after traumatic nerve injury. Annals of Neurology, 2013, 73, 210-223.	5.3	47
24	Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. Journal of Neuromuscular Diseases, 2016, 3, 67-75.	2.6	44
25	Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurology, The, 2021, 20, 1027-1037.	10.2	42
26	A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy. Neurology, 2019, 92, e2109-e2117.	1.1	40
27	215th ENMC International Workshop VCP-related multi-system proteinopathy (IBMPFD) 13â€“15 November 2015, Heemskerk, The Netherlands. Neuromuscular Disorders, 2016, 26, 535-547.	0.6	38
28	ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): Study methodology, recruitment, and baseline demographic and disease characteristics. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 192-203.	1.7	35
29	Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs. Expert Opinion on Investigational Drugs, 2014, 23, 1541-1551.	4.1	35
30	QuantiMus: A Machine Learning-Based Approach for High Precision Analysis of Skeletal Muscle Morphology. Frontiers in Physiology, 2019, 10, 1416.	2.8	35
31	Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle and Nerve, 2019, 59, 201-207.	2.2	35
32	Multisystem proteinopathy: Where myopathy and motor neuron disease converge. Muscle and Nerve, 2021, 63, 442-454.	2.2	33
33	Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity,) Tj ETQq1 1 0.784314 rgBT /O 2016, 26, 136-145.	0.6	31
34	Early Surgical Decompression Restores Neurovascular Blood Flow and Ischemic Parameters in an in Vivo Animal Model of Nerve Compression Injury. Journal of Bone and Joint Surgery - Series A, 2014, 96, 897-906.	3.0	29
35	A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis-associated gene expression. Cell Reports, 2021, 35, 108997.	6.4	28
36	Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis. Science Translational Medicine, 2022, 14, eabi9196.	12.4	27

#	Article	IF	Citations
37	Macrophage Recruitment Follows the Pattern of Inducible Nitric Oxide Synthase Expression in a Model for Carpal Tunnel Syndrome. Journal of Neurotrauma, 2003, 20, 671-680.	3.4	26
38	New family with HSPB 8-associated autosomal dominant rimmed vacuolar myopathy. Neurology: Genetics, 2019, 5, e349.	1.9	24
39	IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis. Journal of the Neurological Sciences, 2021, 430, 118074.	0.6	24
40	Lipid-enriched diet rescues lethality and slows down progression in a murine model of VCP-associated disease. Human Molecular Genetics, 2014, 23, 1333-1344.	2.9	20
41	Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 263-272.	1.7	20
42	Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients. Behavioural Neurology, 2018, 2018, 1-7.	2.1	19
43	Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy. Orphanet Journal of Rare Diseases, 2022, 17, 23.	2.7	19
44	Clinical utility of antiâ€cytosolic 5â€™â€nucleotidase 1A antibody in idiopathic inflammatory myopathies. Annals of Clinical and Translational Neurology, 2021, 8, 571-578.	3.7	18
45	Desert hedgehog is a mediator of demyelination in compression neuropathies. Experimental Neurology, 2015, 271, 84-94.	4.1	17
46	Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology, 2020, 95, e755-e766.	1.1	17
47	Limbâ€girdle muscular dystrophy: A perspective from adult patients on what matters most. Muscle and Nerve, 2019, 60, 419-424.	2.2	15
48	Neuromuscular junction integrity after chronic nerve compression injury. Journal of Orthopaedic Research, 2009, 27, 114-119.	2.3	14
49	Biophysical stimulation induces demyelination via an integrinâ€dependent mechanism. Annals of Neurology, 2012, 72, 112-123.	5.3	14
50	The Role of Neurodiagnostic Studies in Nerve Injuries and Other Orthopedic Disorders. Journal of Hand Surgery, 2007, 32, 1280-1290.	1.6	13
51	Review process for IVIg treatment. Neurology: Clinical Practice, 2018, 8, 429-436.	1.6	9
52	Update on immuneâ€mediated therapies for myasthenia gravis. Muscle and Nerve, 2020, 62, 579-592.	2.2	9
53	Results from a 3-year Non-interventional, Observational Disease Monitoring Program in Adults with GNE Myopathy. Journal of Neuromuscular Diseases, 2021, 8, 225-234.	2.6	9
54	Topical Tranexamic Acid Does Not Affect Electrophysiologic or Neurovascular Sciatic Nerve Markers in an Animal Model. Clinical Orthopaedics and Related Research, 2015, 473, 1074-1082.	1.5	8

#	Article	IF	Citations
55	Sporadic inclusion body myositis misdiagnosed as idiopathic granulomatous myositis. Neuromuscular Disorders, 2016, 26, 741-743.	0.6	7
56	A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene. Neuromuscular Disorders, 2018, 28, 778-786.	0.6	7
57	Examination of the human motor endplate after brachial plexus injury with twoâ€photon microscopy. Muscle and Nerve, 2020, 61, 390-395.	2.2	6
58	237th ENMC International Workshop: GNE myopathy â€“ current and future research Hoofddorp, The Netherlands, 14â€“16 September 2018. Neuromuscular Disorders, 2019, 29, 401-410.	0.6	5
59	First-in-human study of advanced and targeted acid Î±-glucosidase (AT-GAA) (ATB200/AT2221) in patients with Pompe disease: preliminary functional assessment results from the ATB200-02 trial. Molecular Genetics and Metabolism, 2019, 126, S86.	1.1	4
60	Patient reported quality of life in limb girdle muscular dystrophy. Neuromuscular Disorders, 2022, 32, 57-64.	0.6	3
61	Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies. Current Treatment Options in Neurology, 2018, 20, 37.	1.8	2
62	Targeting the Wnt/ÃŸ-Catenin Signaling Pathway After Traumatic Nerve Injury to Improve Functional Recovery. Journal of Hand Surgery, 2014, 39, e13-e14.	1.6	0